Overview#
Beiersdorf AG faced a tough start to 2026, reporting mixed results for the first quarter. The company's revenue fell short of forecasts, leading to a notable decline in its stock price during after-hours trading.
Key Financial Results#
In Q1 2026, Beiersdorf's revenue reached 2.484 billion euros, which is a 7.7% decrease compared to the same period last year. This decline was influenced by unfavorable foreign exchange rates. The company's organic sales, which exclude the effects of currency fluctuations and acquisitions, also fell by 4.6%. The Consumer Business segment saw net sales drop to 2.077 billion euros, while the Tesa segment reported a 4.3% decline in organic sales.
Performance Highlights#
Despite the overall downturn, Beiersdorf's Derma business, which includes popular brands like Eucerin and Aquaphor, showed strong growth, particularly in China. Eucerin's net sales surged by an impressive 87% in this market. The company maintained a solid gross profit margin of 57.71% over the past year, indicating the premium nature of its products.
Market Reaction#
Following the earnings announcement, Beiersdorf's stock price fell by 5.24%, closing at 74.93 euros, down from 79.07 euros. This decline reflects investor disappointment over the earnings miss and a cautious outlook from the company. Currently, the stock is trading just above its 52-week low and has seen a nearly 39% decrease over the past year.
Future Outlook#
Looking ahead, Beiersdorf is projecting modest revenue growth for the remainder of 2026, estimating approximately 11.47 billion euros for the full year. This suggests a gradual recovery as the company navigates current challenges.